<DOC>
	<DOCNO>NCT02999984</DOCNO>
	<brief_summary>This prospective , non-randomized , single-cohort , longitudinal , single-center , clinical study design ass efficacy safety cryopreserved formulation OTL-101 ( autologous CD34+ hematopoietic stem/progenitor cell transduce ex vivo EFS LV encode human ADA gene ) administer ADA-SCID subject age 30 day 17 year age , eligible HLA-matched sibling/family donor meeting inclusion/exclusion criterion . The OTL-101 product infuse minimal interval least 24 hour follow completion reduce intensity conditioning . For subject successfully receive OTL-101 product , PEG-ADA ERT discontinue Day+30 ( +/-3 ) transplant . After discharge hospital , subject see regular interval review history , perform examination draw blood sample assess immunity safety .</brief_summary>
	<brief_title>Autologous Cryopreserved CD34+ Hematopoietic Cells Transduced With EFS-ADA Lentivirus ADA SCID</brief_title>
	<detailed_description>This prospective , non-randomized , single-cohort , longitudinal , single-center , clinical study design ass efficacy safety cryopreserved formulation OTL-101 ( autologous CD34+ hematopoietic stem cell transduce ex vivo EFS LV encode human ADA gene ) administer ADA-SCID subject age 30 day 17 year , eligible HLA-matched sibling/family donor meeting inclusion/exclusion criterion . The aim study assess success treatment overall survival event free survival . Eligible subject hospitalize undergo harvest autologous CD34+ cell . To enable release cell product infusion , product must meet various quality control criterion safety , identity , viability , purity potency . If OTL-101 meet acceptance criterion release , subject readmitted condition prior infusion OTL-101 . For subject successfully receive OTL-101 product , PEG-ADA ERT discontinue Day+30 ( +/-3 ) transplant . After discharge hospital , subject see regular interval review history , perform examination draw blood sample Months 1 , 3 , 6 , 9 , 12 , 18 , 24 . Any medically-indicated intervention determine visit . After Month 24 visit , subject complete study may enter long term registry .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Severe Combined Immunodeficiency</mesh_term>
	<criteria>Eligible subject age â‰¥30 day &lt; 18 year Diagnosis ADASCID Ineligible match family allogeneic bone marrow transplantation Ineligible autologous HSCT per clinical site criterion Other condition , opinion Principal Investigator and/or Co Investigators , contraindicate harvest bone marrow , administration condition infusion transduce cell , indicate inability subject subject 's parent/legal guardian comply protocol Hematologic abnormality , define : Anemia Neutropenia Thrombocytopenia Coagulation abnormality Cytogenetic abnormality Prior allogeneic HSCT cytoreductive conditioning . Pulmonary abnormality Cardiac abnormality Neurologic abnormality Renal abnormality Hepatic/gastrointestinal abnormality Oncologic disease dermatofibrosarcoma protuberans ( DFSP ) Known sensitivity conditioning agent Confirmation infectious disease ( HIV1 , Hepatitis B , Parvovirus B19 ) Pregnancy major congenital anomaly Is likely require treatment study drug permit study protocol Previous gene therapy procedure</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>